Skip to main content
SpringerLink
Log in

The Use of Animal Neuropeptides in the Treatment of Neurological Diseases

  • Reviews
  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

The challenge of the effective treatment of neurological diseases continues to be relevant. Russian neurological practice has used drugs from the neuropeptides group for more than 20 years. The physiological activity of neuropeptides is many times greater than that of non-peptide compounds. Neuropeptides include drugs prepared from animal brains and their synthetic analogs. These drugs differ from each other not only in terms of composition, but also in having different mechanisms of action, though marked neurotrophic and neuroreparative effects are common to all. Large peptides and amino acids act on the principle of replacement therapy; minipeptides affect the nuclear erythroid factor signaling system and bind to molecular targets, and are bioregulators. A specific characteristic of bioregulators is the ability to prolong their action and change their predominant mechanism in response to physiological need. They are regarded as SMART peptides, with high selectivity and efficacy, are safe for use, and are capable of potentiating the effects of other drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lau, J. L. and Dunn, M. K., “Therapeutic peptides: Historical perspectives, current development trends, and future directions,” Bioorg. Med. Chem., 26, No. 10, 2700–2707 (2018), https://doi.org/10.1016/j.bmc.2017.06.052.

    Article  CAS  PubMed  Google Scholar 

  2. Lee, A. C., Harris, J. L., Khanna, K. K., and Hong, J. H., “A comprehensive review on current advances in peptide drug development and design,” Int. J. Mol. Sci., 20, No. 10, 2383 (2019), https://doi.org/10.3390/ijms20102383.

  3. Muttenthaler, M., King, G. F., Adams, D. J., and Alewood, P. F., “Trends in peptide drug discovery,” Nat. Rev. Drug Discov., 20, No. 4, 309–325 (2021), https://doi.org/10.1038/s41573-020-00135-8.

    Article  CAS  PubMed  Google Scholar 

  4. Khavinson, V. Kh., “Therapeutic peptide formulations: past, present, future,” Klinich. Med., 98, No. 3, 165–177 (2020), https://doi.org/10.30629/0023-2149-2020-98-3-165-177.

  5. Putilina, M. V. “Endothelium as a target for novel therapeutic strategies in vascular brain diseases,” Zh. Nevrol. Psikhiatr., 117, No. 10, 122–130 (2017), https://doi.org/10.17116/jnevro2017117101122-130.

  6. Gomazkov, O. A., Functional Biochemistry of Regulatory Peptides, Nauka, Moscow (1993).

    Google Scholar 

  7. Nam, S. H., Park, J., and Koo, H., “Recent advances in selective and targeted drug/gene delivery systems using cell-penetrating peptides,” Arch. Pharm. Res., 46, No. 1, 18–34 (2023), https://doi.org/10.1007/s12272-022-01425-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Moretta, A., Scieuzo, C., Petrone, A., et al., “Antimicrobial peptides: A new hope in biomedical and pharmaceutical fields,” Front. Cell. Infect. Microbiol., 11, No. 8, 456–462 (2014), https://doi.org/10.3389/fcimb.2021.668632.

    Article  CAS  Google Scholar 

  9. Apostolopoulos, V., Bojarska, J., Feehan, J., et al., “Smart therapies against global pandemics: A potential of short peptides,” Front. Pharmacol., 13, 914467 (2025), https://doi.org/10.3389/fphar.2022.914467.

    Article  CAS  Google Scholar 

  10. Zhou, X., Smith, Q. R., and Liu, X., “Brain-penetrating peptides and peptide-drug conjugates for overcoming the blood–brain barrier and combating diseases of the central nervous system,” Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 12, No. 34, 1695 (2021), https://doi.org/10.1002/wnan.1695.

  11. Zhao, L., Liu, J. W., Shi, H. Y., and Ma, Y. M., “Neural stem cell therapy for brain disease,” World J. Stem Cells, 13, No. 9, 1278–1292 (2021), https://doi.org/10.4252/wjsc.v13.i9.1278.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Kulesh, A. A. and Shestakov, V. V., “Poststroke cognitive impairments and the potentials of Cellex therapy,” Zh. Nevrol. Psikhiatr., 116, No. 5, 38–42 (2016), https://doi.org/10.1007/s11055-017-0490-3.

    Article  CAS  Google Scholar 

  13. Gromova, O. A., Torshin, I. Yu., and Gogoleva, I. V., “Mechanisms of neurotrophic and neuroprotective actions of Cerebrolysin in cerebral ischemia,” Zh. Nevrol. Psikhiatr., 114, No. 3–2, 43–50 (2014).

    CAS  Google Scholar 

  14. Putilina, M. V., “Current concepts of small-vessel brain disease,” Zh. Nevrol. Psikhiatr., 119, No. 11, 65–73 (2019), https://doi.org/10.17116/jnevro201911911165.

  15. Bornstein, N. M., Guekht, A., Vester, J., et al., “Safety and efficacy of Cerebrolysin in early post-stroke recovery: a meta-analysis of nine randomized clinical trials,” Neurol. Sci., 39, No. 4, 629–640 (2018), https://doi.org/10.1007/s10072-017-3214-0.

    Article  PubMed  Google Scholar 

  16. Gavrilova, S. I. and Alvarez, A., “Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer’s disease: 30 years of clinical use,” Med. Res. Rev., 45, No. 12, 45–51 (2020), https://doi.org/10.1002/med.21722.

    Article  CAS  Google Scholar 

  17. Gomazkov, O. A., “Cortexin: molecular mechanisms and targets of neuroprotective activity,” Zh. Nevrol. Psikhiatr., 115, No. 8, 99–104 (2015), https://doi.org/10.17116/jnevro20151158199-104.

  18. Pinelis, V. G., Storozhevykh, T. P., Surin, A. M., et al., “Neuroprotective effects of cortagen, cortexin and semax on glutamate neurotoxicity,” J. Peptide Sci., 14, No. 8, 159–160 (2008).

    Google Scholar 

  19. Soudy, R., Kimura, R., and Patel, A., “Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model,” Sci. Rep., 9, 10942 (2019), https://doi.org/10.1038/s41598-019-47255-9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Yakovlev, A. A. and Gulyaeva, N. V., “Molecular partners of Cortexin in the brain,” Neirokhimiya, 34, No. 1, 91–96 (2017), https://doi.org/10.7868/S1027813316040166.

    Article  Google Scholar 

  21. Yakovlev, A. A., Lyzhin, A. A., Khaspekov, L. G., et al., “The peptide-based drug cortexin inhibits brain caspase-8,” Biochemistry (Moscow), Suppl. Series B: Biomed Chem., 11, No. 2, 134–138 (2017), https://doi.org/10.1134/s1990750817020111.

    Article  Google Scholar 

  22. Lee, J. and Kim, C., “Peptide materials for smart therapeutic applications,” Macromol. Res., 29, 2–14 (2021), https://doi.org/10.1007/s13233-021-9011-x.

    Article  CAS  Google Scholar 

  23. Putilina, M. V., Mutovina, Z. Yu., and Kurushina, O. V., et al., “Determination of the prevalence of post-Covid syndrome and assessment of the efficacy of the drug Cortexin in the treatment of neurological disorders in patients with post-Covid syndrome. Results of the CORTEX multicenter observational program,” Zh. Nevrol. Psikhiat., 122, No. 1, 84–90 (2022), https://doi.org/10.17116/jnevro202212201184.

  24. Fedin, A. I., Bel’skaya, G. N., Kurushina, O. V., et al., “Dose-dependent effects of Cortexin in chronic cerebral ischemia (results of a multicenter randomized controlled trial),” Zh. Nevrol. Psikhiatr., 118, No. 9, 35–42 (2018), https://doi.org/10.17116/jnevro201811809135.

  25. Putilina, M. V., “Pathogenetic approaches to the therapy of sleep disorders in comorbid patients,” Zh. Nevrol. Psikhiatr., 122, No. 11, 11–16 (2022), https://doi.org/10.17116/jnevro202212211111.

  26. Tyurenkov, I. N., Kurkin, D. V., and Kalatanova, A. V., et al., “A comparative study of the effects of Cortexin, Cerebrolysin, and Actovegin on memory, cerebral circulation, and hippocampus structure in rats with chronic cerebrovascular accident,” Zh. Nevrol. Psikhiatr., 120, No. 8, 83–89 (2020), https://doi.org/10.17116/jnevro202012008183.

  27. Gromova, O. A., Torshin, I. Yu., Putilina, M. V., et al., “Selection of neuroprotective therapies in patients with chronic cerebral ischemia, taking account of the synergy of drug interactions,” Zh. Nevrol. Psikhiat., 120, No. 8, 42–50 (2020), https://doi.org/10.17116/jnevro202012008142.

  28. Putilina, M. V. and Teplova, N. V., “Drug synergy as basis for rational neuroprotection,” Zh. Nevrol. Psikhiatr., 122, No. 5, 17–22 (2022), https://doi.org/10.17116/jnevro202212205117.

  29. Lubell, W. D., “Peptide-based drug development,” Biomedicines, 10, No. 8, 2037 (2022), https://doi.org/10.3390/biomedicines10082037.

    Article  Google Scholar 

  30. Putilina, M. V., “Combined neuroprotective therapy for cerebrovascular diseases,” Vrach, 4, No. 3, 69–73 (2012).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pirogov Russian National Research Medical University, Russian Ministry of Health, Moscow, Russia

    M. V. Putilina

Authors
  1. M. V. Putilina
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. V. Putilina.

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 123, No. 9, pp. 37–42, September, 2023.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Putilina, M.V. The Use of Animal Neuropeptides in the Treatment of Neurological Diseases. Neurosci Behav Physi 54, 205–209 (2024). https://doi.org/10.1007/s11055-024-01586-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-024-01586-x

Keywords

Search

Navigation